Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

News Daily News

Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies

Michael O'Riordan

December 19, 2023

Who Benefits Most From Semaglutide and How Long Will That Take?

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

December 19, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

Optimal Care Reported in Less Than Half of Adults With ASCVD

News Daily News

Optimal Care Reported in Less Than Half of Adults With ASCVD

Yael L. Maxwell

December 05, 2023

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

News Daily News

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

December 01, 2023

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

News Daily News

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

Michael O'Riordan

November 21, 2023

Mortality Risk Varies Among Patients With Very High LDL Levels

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

October 10, 2023

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

Mortality, CVD Benefits Seen at Relatively Low Daily Step Counts

News Daily News

Mortality, CVD Benefits Seen at Relatively Low Daily Step Counts

Michael O'Riordan

September 08, 2023

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

News Daily News

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

August 08, 2023

CVD Risk Reduction With Exercise Also Seen in ‘Weekend Warriors’

News Daily News

CVD Risk Reduction With Exercise Also Seen in ‘Weekend Warriors’

Michael O'Riordan

July 24, 2023

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.